Adalimumab (Humira) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohns disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. Adalimumab binds to the TNF alpha (tumor necrosis factor-alpha), and blocks its interaction with TNF alpha receptors, reducing the inflammatory response of autoimmune diseases. Anti-Adalimumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Adalimumab.
Clonality:
Polyclonal
Purity:
Antigen affinity chromatography
Form:
Purified
Application Dilute:
ELISA detection: 0.05-0.2 µg/ml
* VAT and and shipping costs not included. Errors and price changes excepted
